Publications en collaboration avec des chercheurs de Hospital Universitario de la Princesa (19)

2024

  1. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2023

  1. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)

    Scientific Reports

2022

  1. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

    Oncotarget, Vol. 13, Núm. 1, pp. 812-827

2021

  1. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

    European Journal of Cancer, Vol. 159, pp. 174-181

  2. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  3. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553

  4. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection

    Lung Cancer, Vol. 153, pp. 25-34

2018

  1. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

    BMC Cancer, Vol. 18, Núm. 1

  2. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38

  3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

2017

  1. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

    Journal of the National Cancer Institute, Vol. 109, Núm. 9

  2. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

2016

  1. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study

    Melanoma Research, Vol. 26, Núm. 3, pp. 278-283

2015

  1. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

    Scientific Reports, Vol. 5

2013

  1. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. the large experience of the spanish national tumor registry (RGETNE)

    Neuroendocrinology, Vol. 98, Núm. 2, pp. 156-168

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2010

  1. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)

    Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803

2009

  1. Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

    PLoS ONE, Vol. 4, Núm. 5

2004

  1. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: Randomized phase II trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study

    Annals of Oncology, Vol. 15, Núm. 1, pp. 79-87